142 related articles for article (PubMed ID: 26177509)
1. Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.
Sivagnanalingam U; Balys M; Eberhardt A; Wang N; Myers JR; Ashton JM; Becker MW; Calvi LM; Mendler JH
PLoS One; 2015; 10(7):e0132375. PubMed ID: 26177509
[TBL] [Abstract][Full Text] [Related]
2. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Mendler JH; Maharry K; Radmacher MD; Mrózek K; Becker H; Metzeler KH; Schwind S; Whitman SP; Khalife J; Kohlschmidt J; Nicolet D; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2012 Sep; 30(25):3109-18. PubMed ID: 22753902
[TBL] [Abstract][Full Text] [Related]
3. Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?
DeAngelo DJ; Stein EM; Ravandi F
Am Soc Clin Oncol Educ Book; 2016; 35():e302-12. PubMed ID: 27249736
[TBL] [Abstract][Full Text] [Related]
4. Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion.
Coltoff A; Houldsworth J; Keyzner A; Renteria AS; Mascarenhas J
Ann Hematol; 2018 Jul; 97(7):1155-1167. PubMed ID: 29704019
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.
Hickey CJ; Schwind S; Radomska HS; Dorrance AM; Santhanam R; Mishra A; Wu YZ; Alachkar H; Maharry K; Nicolet D; Mrózek K; Walker A; Eiring AM; Whitman SP; Becker H; Perrotti D; Wu LC; Zhao X; Fehniger TA; Vij R; Byrd JC; Blum W; Lee LJ; Caligiuri MA; Bloomfield CD; Garzon R; Marcucci G
Blood; 2013 Jan; 121(1):159-69. PubMed ID: 23100311
[TBL] [Abstract][Full Text] [Related]
6. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.
Khan M; Cortes J; Kadia T; Naqvi K; Brandt M; Pierce S; Patel KP; Borthakur G; Ravandi F; Konopleva M; Kornblau S; Kantarjian H; Bhalla K; DiNardo CD
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28933735
[TBL] [Abstract][Full Text] [Related]
8. Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia.
Nachmias B; Krichevsky S; Filon D; Even-Or E; Gatt ME; Saban R; Avni B; Grisariu S; Aumann S; Vainstein V
Acta Haematol; 2022; 145(6):642-649. PubMed ID: 35933982
[TBL] [Abstract][Full Text] [Related]
9. Chemogenomic Landscape of
Simon L; Lavallée VP; Bordeleau ME; Krosl J; Baccelli I; Boucher G; Lehnertz B; Chagraoui J; MacRae T; Ruel R; Chantigny Y; Lemieux S; Marinier A; Hébert J; Sauvageau G
Clin Cancer Res; 2017 Nov; 23(22):6969-6981. PubMed ID: 28855357
[No Abstract] [Full Text] [Related]
10. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia with t(14;21) involving RUNX1 and SYNE2: A novel favorable-risk translocation?
Foley N; Van Ziffle J; Yu J; Qi Z; Grenert JP; Yeh I; Bastian B; Kogan S; Mannis GN
Cancer Genet; 2017 Oct; 216-217():74-78. PubMed ID: 29025598
[TBL] [Abstract][Full Text] [Related]
12. Isolated Bone Marrow Non-Langerhans Cell Histiocytosis Preceding RUNX1-Mutated Acute Myeloid Leukemia: Case Report and Literature Review.
Al Mugairi A; Al Turki S; Salama H; Al Ahmadi K; Abuelgasim KA; Damlaj M
Am J Clin Pathol; 2019 May; 151(6):638-646. PubMed ID: 30989185
[TBL] [Abstract][Full Text] [Related]
13. Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.
Höllein A; Jeromin S; Meggendorfer M; Fasan A; Nadarajah N; Kern W; Haferlach C; Haferlach T
Leukemia; 2018 Oct; 32(10):2270-2274. PubMed ID: 29568097
[No Abstract] [Full Text] [Related]
14. RUNX1 Mutations Can Lead to Aberrant Expression of CD79a and PAX5 in Acute Myelogenous Leukemias: A Potential Diagnostic Pitfall.
Menter T; Lundberg P; Wenzel F; Dirks J; Fernandez P; Friess D; Dirnhofer S; Tzankov A
Pathobiology; 2019; 86(2-3):162-166. PubMed ID: 30396184
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a new myeloid leukemia cell line with normal cytogenetics (CG-SH).
Munker R; Nordberg ML; Veillon D; Williams BJ; Roggero A; Kern W; Dicker F; Haferlach T
Leuk Res; 2009 Oct; 33(10):1405-8. PubMed ID: 19414191
[TBL] [Abstract][Full Text] [Related]
16. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models.
Lal D; Park JA; Demock K; Marinaro J; Perez AM; Lin MH; Tian L; Mashtare TJ; Murphy M; Prey J; Wetzler M; Fetterly GJ; Wang ES
Mol Cancer Ther; 2010 Oct; 9(10):2737-51. PubMed ID: 20924124
[TBL] [Abstract][Full Text] [Related]
17. Accurate and Sensitive Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Deep Sequencing of Single Nucleotide Variations.
Delsing Malmberg E; Rehammar A; Pereira MB; Abrahamsson J; Samuelsson T; Ståhlman S; Asp J; Tierens A; Palmqvist L; Kristiansson E; Fogelstrand L
J Mol Diagn; 2019 Jan; 21(1):149-162. PubMed ID: 30273780
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
[TBL] [Abstract][Full Text] [Related]
19. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
[TBL] [Abstract][Full Text] [Related]
20. RUNX1/CEBPA Mutation in Acute Myeloid Leukemia Promotes Hypermethylation and Indicates for Demethylation Therapy.
Romanova EI; Zubritskiy AV; Lioznova AV; Ogunleye AJ; Golotin VA; Guts AA; Lennartsson A; Demidov ON; Medvedeva YA
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
